177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
Contact: Study coordinator (Tomasz Lachcik) · tomasz.lachcik@gliwice.nio.gov.pl · +48322789791
Contact: Principal Investigator (Daria Handkiewicz-Junak, Prof.)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · El Paso, United States

A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Wuhan, China

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chengdu, China · Tianjin, China